Protalix BioTherapeutics, Inc is a biopharmaceutical company based in Hackensack, NJ, dedicated to developing and bringing to market recombinant therapeutic proteins with clinically improved profiles. They utilize their ProCellEx plant cell-based expression system to produce plant-based proteins that offer better therapeutic benefits. With a focus on innovative technology and a robust pipeline of potential treatments, Protalix aims to address various medical conditions and improve patient outcomes.
Protalix BioTherapeutics, Inc is actively engaged in clinical studies and collaborations to advance their pipeline of therapeutic proteins. Their lead candidate, pegunigalsidase alfa (PRX-102), is currently in Phase III for the treatment of Fabry disease, while alidornase alfa (PRX-110) is being developed for inhaled indications in respiratory diseases. With a commitment to scientific excellence and a plant-based protein expression system, Protalix is poised to make significant contributions to the field of biopharmaceuticals and improve the lives of patients worldwide.
Generated from the website
